SGS
SGS is recorded as a service provider in 185 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 185 trials · Latest update first
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
Sponsor Scleroderma Research Foundation
- Start (EU)
- Latest update
- Estimated end
A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- Recruitment began on 1 March 2022, and 98 participants were randomized at 57 sites in 19 countries.
- A May 2022 amendment changed the primary endpoint from complete remission on minimal OCS to CRoff at week 36 and added CRmin and IGA-BP-off-OCS secondary endpoints.
- Infection-related eligibility criteria were tightened across amendments, including exclusion of active or chronic infections and later clinically significant active infection unresolved before baseline.
- A March 2023 amendment added exclusions for latent infection, severe renal impairment, specified safety or procedure-affecting conditions, concurrent interventional-study enrollment, inadequately treated HIV, and recent live or live-attenuated vaccination.
- Sponsor confirmation of participant eligibility was removed in the March 2023 amendment.
- The March 2023 amendment required at least 30 minutes of on-site safety monitoring after investigational-product administration, and this requirement was removed in February 2024.
- The Day 10 PK sampling requirement in Part A was clarified to require samples from at least 28 participants rather than all participants.
- All adverse events in the MedDRA Infections and Infestations system organ class were designated adverse events of special interest in the May 2022 amendment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with advanced prostate cancer
Sponsor Debiopharm International SA
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Not reported
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.
Sponsor Galapagos
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Of 84 activated sites, 68 screened at least one subject and 57 randomized subjects across Argentina, Bulgaria, Chile, Germany, Spain, France, Georgia, Hungary, Peru, Poland, Puerto Rico, and the US.
These findings describe the trial, not the service provider’s performance or responsibility.
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open-label extension phase.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
An open-label, single-arm, multicenter, phase 3 study to assess pharmacokinetics, safety and tolerability of iptacopan in pediatric PNH patients aged 2 to <18 years of age
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in participants with active lupus nephritis (SIRIUS-LN)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
Sponsor Agomab Spain S.L.U.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for SGS?
The 2026-10-09 snapshot links SGS to 185 distinct CTIS trials. Recorded services include Laboratory services, Data management, Statistical analysis, Safety reporting & pharmacovigilance, among 76 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for SGS?
The most frequently recorded therapeutic areas are Immunology, Neurology, Rheumatology, Endocrinology. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to SGS conducted?
The linked trials record locations in 27 countries, including Germany, Spain, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where SGS delivered services.
What can this page tell me about SGS's trial experience?
Browse 185 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 10 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 9 recorded name variants under SGS. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- SGS Analytics Germany GmbH
- SGS Analytics Switzerland AG
- SGS Aster
- SGS Belgium
- SGS France
- SGS Institut Fresenius GmbH
- SGS North America Inc.
- SGS proderm GmbH
- Sgs - LSS